Pharma BD Deal Intelligence
Novartis AG / Advanced Accelerator Applications
2017 · Acquisition/Merger · $3.9B · Complete
Announcement Sentiment
80
Strongly positive
Outcome Score
82
Worked — the deal delivered on its rationale.
Novartis acquired AAA for $3.9B for nuclear medicine and radiopharmaceuticals.
Key facts
- Announced Oct 30, 2017
- Closed Jan 22, 2018
- Deal value $3.9B
- Deal type Acquisition/Merger
- Therapeutic area Oncology
- Indications Neuroendocrine tumors (radioligand therapy/nuclear medicine)
- Key assets Lutathera
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals